Effects of insulin-like growth factor 1 receptor and its inhibitor AG1024 on the progress of lung cancer

Abstract

The type 1 insulin-like growth factor receptor (IGF-1R) and its downstream signaling components have been increasingly recognized to drive the development of malignancies, including non-small cell lung cancer (NSCLC). This study aimed to investigate the effects of IGF-1R and its inhibitor, AG1024, on the progression of lung cancer. Tissue microarray and immunohistochemistry were employed to detect the expressions of IGF-1 and IGF-1R in NSCLC tissues (n=198). Western blotting was used to determine the expressions of IGF-1 and phosphorylated IGF-1R (p-IGF-1R) in A549 human lung carcinoma cells, and MTT assay to measure cell proliferation. Additionally, the expressions of IGF-1, p-IGF-1R and IGF-1R in a mouse model of lung cancer were detected by Western blotting and real-time fluorescence quantitative polymerase chain reaction (FQ-PCR), respectively. The results showed that IGF-1 and IGF-1R were overexpressed in NSCLC tissues. The expression levels of IGF-1 and p-IGF-1R were significantly increased in A549 cells treated with IGF-1 as compared to those treated with IGF-1+AG1024 or untreated cells. In the presence of IGF-1, the proliferation of A549 cells was significantly increased. The progression of lung cancer in mice treated with IGF-1 was significantly increased as compared to the group treated with IGF-1+AG1024 or the control group, with the same trend mirrored in IGF-1/p-IGF-1R/IGF-1R at the protein and/or mRNA levels. It was concluded that IGF-1 and IGF inhibitor AG1024 promotes lung cancer progression.

Keywords

lung cancer / mouse lung adenocarcinoma model / insulin-like growth factor-1 receptor / AG1024

References

[1] JemalA, BrayF, CenterMM, et al. . Global cancer statistics. CA Cancer J Clin, 2011, 61(2): 69-90 PMID: 21296855

[2] LiaoY, AbelU, GrobholzR, et al. . Up-regulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade. Hum Patho, 2005, 36(11): 1186-1196

[3] LiaoYD, ZhouS, ZhaoJP, et al. . Expression and significance of IGF1, IGF1R and AKT, the components of IGF signaling pathway, in primary adenocarcinoma of the lung. J Prac Oncol (Chinese), 2006, 21(1): 15-19

[4] FuSL, LiaoYD, YouLK, et al. . The correlation between circulating insulin-like growth factor-I in blood and clinicopathological parameters in non-small cell lung cancer. Acta Med Univ Sci Technol Huazhong (Chinese), 2009, 38(6): 821-823

[5] SamaniAA, YakarS L, RoithD, et al. . The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev, 2007, 28(1): 20-47 PMID: 16931767

[6] XuP P J, LiuYY, et al. . Clinical significance of insulin-like growth factor 1 and insulin like growth factor binding protein 3 in serum and bronchoalveolar lavagae fluids of patients with lung cancer. J Clin Intern Med (Chinese), 2007, 24(8): 541-543

[7] FuSL, LiaoYD, YouLK, et al. . The level of insulin-like growth factor-I in blood circulation in patients with non-small cell lung cancer after surgery and its clinical significance. Zhongguo Zhongliu (Chinese), 2009, 19(9): 667-670

[8] KangKF, WangXW, ChenXW, et al. . Expression and clinical significance of Beclin1 and NF-?B p65 protein in primary human hepatocellular carcinoma. Shi Jie Hua Ren Xiao Hua Za Zhi (Chinese), 2008, 16(20): 2244-2247

[9] KawasakiH, AltieriDC, LuCD, et al. . Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res, 1998, 58(22): 5071-5074 PMID: 9823313

[10] YangXR, PfeifferRM, Garcia-ClosasM, et al. . Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics, and risk factor associations in a population-based study. Cancer Res, 2007, 67(21): 10608-10617 PMID: 17968031

[11] MarquezDC, PietrasRJ. Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells. Oncogene, 2001, 20(39): 5420-5430 PMID: 11571639

[12] ChangMM, LovettJ. A laboratory exercise illustrating the sensitivity and specificity of Western blot analysis. Biochem Mol Biol Educ, 2011, 39(4): 291-297 PMID: 21774057

[13] JiangYG, ChenJK, WuZL. Promotive effect of diethylstilbestrol on urethan-induced mouse lung tumorigenesis. Chemosphere, 2000, 41(1-2): 187-190 PMID: 10819200

[14] LiSQ, XiaoBL, DongQN, et al. . Experimental conditions of mouse lung tumors induced by short-term trials. Zhong Guo Yao Li Xue He Du Li Xue Za Zhi (Chinese), 1993, 7(1): 68-72

[15] HechtSS, IsaacsS, TrushinN. Lung tumor induction in A/J mice by the tobacco smoke carcinogens 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and benzo[a]pyrene: a potentially useful model for evaluation of chemopreventive agents. Carcinogenesis, 1994, 15(12): 2721-2725 PMID: 8001227

[16] JassamN, BellSM, SpeirsV, et al. . Loss of expression of oestrogen receptor beta in colon cancer and its association with Dukes’ staging. Oncol Rep, 2005, 14(1): 17-21 PMID: 15944762

[17] YamagamiH, MatsumotoT, FujiwaraN, et al. . Trehalose 6,6’-dimycolate (cord factor) of Mycobacterium tuberculosis induces foreign-body-and hypersensitivitytype granulomas in mice. Infect Immun, 2001, 69(2): 810-815 PMCID: 97956 PMID: 11159972

[18] HamasakiN, IsowaK, KamadaK, et al. . In vivo administration of mycobacterial cord factor (Trehalose 6, 6’-dimycolate) can induce lung and liver granulomas and thymic atrophy in rabbits. Infect Immun, 2000, 68(6): 3704-3709 PMCID: 97662 PMID: 10816531

[19] StabileLP, DacicS, LandSR, et al. . Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin Cancer Res, 2011, 17(1): 154-164 PMCID: 3064257 PMID: 21062926

[20] LiZ, ZhuH, MaB, et al. . Inhibitory effect of Bifidobacterium infantis-mediated sKDR prokaryotic expression system on angiogenesis and growth of Lewis lung cancer in mice. BMC Cancer, 2012, 12(1): 155 PMCID: 3404897 PMID: 22536942

[21] SiegelR, WardE, BrawleyO, et al. . Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin, 2011, 61(4): 212-236 PMID: 21685461

[22] WuJY, YuCJ, YangCH, et al. . First-or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer. Am J Respir Crit Care Med, 2008, 178(8): 847-853 PMID: 18583573

[23] CoxME, GleaveME, ZakikhaniM, et al. . Insulin receptor expression by human prostate cancers. Prostate, 2009, 69(1): 33-40 PMID: 18785179

[24] CreightonCJ, CasaA, LazardZ, et al. . Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol, 2008, 26(25): 4078-4085 PMCID: 2654368 PMID: 18757322

[25] CamidgeDR, DziadziuszkoR, HirschFR. The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancers. Clin Lung Cancer, 2009, 10(4): 262-272 PMID: 19632946

[26] GongY, YaoE, ShenR, et al. . High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One, 2009, 4(10): 7273

[27] LawJH, HabibiG, HuK, et al. . Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res, 2008, 68(24): 10238-10246 PMID: 19074892

[28] KimHJ, LitzenburgerBC, CuiX, et al. . Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail. Mol Cell Biol, 2007, 27(8): 3165-3175 PMCID: 1899918 PMID: 17296734

[29] YehJ, LitzJ, HauckP, et al. . Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt. Lung Cancer, 2008, 60(2): 166-174 PMID: 18006183

[30] Del MonteP, LaurinoC, ArvigoM, et al. . Effects of alpha-interferon on insulin-like growth factor-I, insulinlike growth factor-II and insulin-like growth factor binding protein-3 secretion by a human lung cancer cell line in vitro. J Endocrinol Invest, 2005, 28(5): 432-439 PMID: 16075927

[31] LiaoYD, LongQH, ZhouS, et al. . Expression and prognostic significance of in sulin-like growth factor 1 in non-small cell lung cancer. Zhong Guo Zhong Liu (Chinese), 2005, 15(4): 321-325

[32] HoldawayIM, LethabyAE, MasonBH, et al. . Effect of breast surgery on serum levels of insulin-like growth factors (IGF-I, IGF-II, and IGF binding protein-3) in women with benign and malignant breast lesions. Ann Surg Oncol, 2001, 8(1): 25-31 PMID: 11206220

[33] FranciosiCM, PiacentiniMG, ContiM, et al. . IGF-1 and IGF-1BP3 in gastric adenocarcinoma. Preliminary study. Hepatogastroenterology, 2003, 50(49): 297-300

[34] KarpDD, Paz-AresLG, NovelloS, et al. . Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol, 2009, 27(15): 2516-2522 PMID: 19380445

[35] FidlerMJ, ShersherDD, BorgiaJA, et al. . Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls. Ther Adv Med Oncol, 2012, 4(2): 51-60 PMCID: 3296080 PMID: 22423264

[36] GualbertoA, Dolled-FilhartM, GustavsonM, et al. . Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. Clin Cancer Res, 2010, 16(18): 4654-4665 PMCID: 2952544 PMID: 20670944

[37] KodamaY, BaxterRC, MartinJL. Insulin-like growth factor-I inhibits cell growth in the a549 non-small lung cancer cell line. Am J Respir Cell Mol Biol, 2002, 27(3): 336-344 PMID: 12204896

[38] CosaceanuD, CarapanceaM, AlexandruO, et al. . Comparison of three approaches for inhibiting insulin-like growth factor I receptor and their effects on NSCLC cell lines in vitro. Growth Factors, 2007, 25(1): 1-8 PMID: 17454144